The case for & against
Bull & Bear analysis
Boston Scientific Corporation (NASDAQ: BSX) is a global leader in the medical device industry, specializing in the development and manufacturing of devices for interventional medicine, particularly in cardiovascular, rhythm management, urology, and endoscopy markets. With a robust portfolio and a strong focus on innovation, the company plays a pivotal role in improving patient care and outcomes. Boston Scientific is part of the rising trend in health technology, capitalizing on advancements in medical devices and treatments to capture a broader market presence.
Bull says
- ↑Q1 2026 revenue $5.203B (+11.6% YoY) and EPS $0.80 (+6% YoY) beat consensus
- ↑Proposed Penumbra acquisition closing in 2026 strengthens interventional oncology
- ↑$5B buyback supported by projected $4B free cash flow in FY26
- ↑26 analyst buys, $55–$106 target range implies >20% upside
- ↑Favorable balance sheet quality and 0.46 dividend yield attract investors
- ↑Upcoming Watchman product launches bolster long-term growth prospects
Bear says
- ↓Full-year organic growth guidance trimmed from 10–12% to 6.5–8% for 2026
- ↓EP segment market share under pressure from Medtronic and J&J competition
- ↓Gross margin down 100bps YoY to 70.5% due to tariffs and mix shifts
- ↓Negative earnings yield and weak momentum suggest stock overvaluation
- ↓Urology supply chain constraints may limit availability through 2026
- ↓Watchman trial outcomes uncertain, any adverse data could derail growth
Investment themes with BSX
Devices and instruments for medical treatment
Services and products for aging population
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- First quarter represented a solid quarter for Boston Scientific, with total company organic sales growth of 9.4% versus our guidance range of 8.5% to 10%.
- First quarter adjusted EPS of $0.80 through 6%, achieving a high-end of our guidance range of $0.78 to $0.80. And Q1 adjusted operating margin was 28%.
- Importantly, we remain convicted in the future of Boston Scientific. We have a strong global team committed to high performance, and we continue to invest in key new and existing markets, which we believe will enable us to deliver on our fundamental goal of driving differentiated performance over the LRP.
Bear points
- 2026 has proven to be a more challenging year than we initially expected.
- we expect that growth in demand will continue to improve with the annualization of the accurate discontinuation in 2Q and ongoing momentum from Farrah Falls, Watchman, and other key products.
- which is expected to annualize in second quarter.